<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">35568265</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1872-7980</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>540</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>12</Day>
            </PubDate>
          </JournalIssue>
          <Title>Cancer letters</Title>
          <ISOAbbreviation>Cancer Lett</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The antidepressant imipramine inhibits breast cancer growth by targeting estrogen receptor signaling and DNA repair events.</ArticleTitle>
        <Pagination>
          <StartPage>215717</StartPage>
          <MedlinePgn>215717</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.canlet.2022.215717</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0304-3835(22)00201-4</ELocationID>
        <Abstract>
          <AbstractText>Aberrant activities of various cell cycle and DNA repair proteins promote cancer growth and progression and render them resistant to therapies. Here, we demonstrate that the anti-depressant imipramine blocks growth of triple-negative (TNBC) and estrogen receptor-positive (ER+) breast cancers by inducing cell cycle arrest and by blocking heightened homologous recombination (HR) and non-homologous end joining-mediated (NHEJ) DNA repair activities. Our results reveal that imipramine inhibits the expression of several cell cycle- and DNA repair-associated proteins including E2F1, CDK1, Cyclin D1, and RAD51. In addition, we show that imipramine inhibits the growth of ER + breast cancers by inhibiting the estrogen receptor- α (ER-α) signaling. Our studies in preclinical mouse models and ex vivo explants from breast cancer patients show that imipramine sensitizes TNBC to the PARP inhibitor olaparib and endocrine resistant ER + breast cancer to anti-estrogens. Our studies suggest that repurposing imipramine could enhance routine care for breast cancer patients. Based on these results, we designed an ongoing clinical trial, where we are testing the efficacy of imipramine for treating patients with triple-negative and estrogen receptor-positive breast cancer. Since aberrant DNA repair activity is used by many cancers to survive and become resistant to therapy, imipramine could be used alone and/or with currently used drugs for treating many aggressive cancers.</AbstractText>
          <CopyrightInformation>Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Timilsina</LastName>
            <ForeName>Santosh</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cell Systems and Anatomy, UT Health, San Antonio, USA; Greehey Children's Cancer Research Institute, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rajamanickam</LastName>
            <ForeName>Subapriya</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Greehey Children's Cancer Research Institute, USA; Department of Molecular Medicine, UT Health, San Antonio, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rao</LastName>
            <ForeName>Arhan</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Health Careers High School, San Antonio, TX, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Subbarayalu</LastName>
            <ForeName>Panneerdoss</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cell Systems and Anatomy, UT Health, San Antonio, USA; Greehey Children's Cancer Research Institute, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nirzhor</LastName>
            <ForeName>Saif</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cell Systems and Anatomy, UT Health, San Antonio, USA; Greehey Children's Cancer Research Institute, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Abdelfattah</LastName>
            <ForeName>Nourhan</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Houston Methodist, Houston, TX, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Viswanadhapalli</LastName>
            <ForeName>Suryavathi</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, UT Health, San Antonio, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Yidong</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Greehey Children's Cancer Research Institute, USA; Department of Epidemiology and Statistics, UT Health, San Antonio, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jatoi</LastName>
            <ForeName>Ismail</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, UT Health, San Antonio, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Brenner</LastName>
            <ForeName>Andrew</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, UT Health, San Antonio, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rao</LastName>
            <ForeName>Manjeet K</ForeName>
            <Initials>MK</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cell Systems and Anatomy, UT Health, San Antonio, USA; Greehey Children's Cancer Research Institute, USA. Electronic address: raom@uthscsa.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vadlamudi</LastName>
            <ForeName>Ratna</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, UT Health, San Antonio, USA. Electronic address: vadlamudi@uthscsa.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kaklamani</LastName>
            <ForeName>Virginia</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, UT Health, San Antonio, USA. Electronic address: Kaklamani@uthscsa.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>12</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Ireland</Country>
        <MedlineTA>Cancer Lett</MedlineTA>
        <NlmUniqueID>7600053</NlmUniqueID>
        <ISSNLinking>0304-3835</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Breast cancer</Keyword>
        <Keyword MajorTopicYN="N">DNA damage</Keyword>
        <Keyword MajorTopicYN="N">DNA repair</Keyword>
        <Keyword MajorTopicYN="N">Drug repurposing</Keyword>
        <Keyword MajorTopicYN="N">Estrogen receptor</Keyword>
        <Keyword MajorTopicYN="N">Imipramine</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>14</Day>
          <Hour>19</Hour>
          <Minute>34</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35568265</ArticleId>
        <ArticleId IdType="doi">10.1016/j.canlet.2022.215717</ArticleId>
        <ArticleId IdType="pii">S0304-3835(22)00201-4</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
